FDA Issues 30 Warning Letters to GLP-1 Telehealth Companies for Misleading Marketing
The FDA sent warning letters to 30 telehealth companies for making false or misleading marketing claims about compounded GLP-1 medications, including claims of equivalence to FDA-approved products.
Key Takeaways
- 30 telehealth companies received FDA warning letters in March 2026
- Violations included false equivalence claims between compounded and brand-name GLP-1s
- Compounded medications are legal but are not FDA-approved products
- Patients should ask their provider about any warning letters received
What Happened
On March 3, 2026, the FDA announced it had issued warning letters to 30 telehealth companies marketing compounded versions of GLP-1 receptor agonists, including semaglutide and tirzepatide. The FDA determined that these companies made claims about their compounded products that were false or misleading under federal law.
What the FDA Found
The warning letters cited multiple types of violations. Companies were making claims that compounded semaglutide is equivalent to or the same as brand-name Ozempic or Wegovy. Some companies implied FDA approval of their compounded formulations. Others made unsupported efficacy claims or failed to disclose that compounded drugs are not FDA-approved.
What This Means for Patients
If you are currently receiving compounded GLP-1 medications from a telehealth provider, this does not necessarily mean your medication is unsafe. However, you should be aware that compounded medications have not undergone the same FDA review process as approved drugs. Ask your provider whether they have received a warning letter and how they are addressing any concerns.
What to Do
Review any marketing materials from your provider with a critical eye. Legitimate providers will not claim their compounded medications are identical to FDA-approved products. If you have concerns, check this page for your provider to see their current FDA status, or consult with your healthcare provider directly.
Affected Companies
Source: View original on FDA.gov
Frequently Asked Questions
Does this mean compounded semaglutide is unsafe?
Not necessarily. The warning letters were about marketing claims, not product safety. However, patients should be aware that compounded medications have not undergone the same FDA review as approved drugs like Ozempic or Wegovy.
How do I know if my telehealth provider received a warning letter?
You can search for your provider on this page or check the FDA warning letters database directly at FDA.gov. Providers are required to respond to warning letters within 15 business days.
Should I stop taking my compounded GLP-1 medication?
Do not stop taking any medication without consulting your healthcare provider. If you have concerns about your current treatment, discuss them with the prescribing physician.
Disclaimer: This article summarizes publicly available FDA data for informational purposes only. It is not medical or legal advice. Always consult your healthcare provider and verify with official FDA sources before making decisions about your treatment.
Related Safety Guides
GLP-1 Safety Alerts
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.